c4d – the birmingham uk experience desley neil, majid mukadam, david briggs* uhbnhsft, nhsbt*...
Post on 15-Jan-2016
216 views
TRANSCRIPT
![Page 1: C4d – The Birmingham UK Experience Desley Neil, Majid Mukadam, David Briggs* UHBNHSFT, NHSBT* Birmingham](https://reader036.vdocuments.mx/reader036/viewer/2022070412/56649d2b5503460f94a005ac/html5/thumbnails/1.jpg)
C4d – The Birmingham UK Experience
Desley Neil, Majid Mukadam, David Briggs*UHBNHSFT, NHSBT*
Birmingham
![Page 2: C4d – The Birmingham UK Experience Desley Neil, Majid Mukadam, David Briggs* UHBNHSFT, NHSBT* Birmingham](https://reader036.vdocuments.mx/reader036/viewer/2022070412/56649d2b5503460f94a005ac/html5/thumbnails/2.jpg)
Method
• C4d staining performed routinely on all EMBs from May 2004.• May 2004 – May 2008
– 1443 biopsies in 163 patients with 166 transplants– reports for Grade of C4d staining
• 71 (4.9%) unreported – 14 missing , rest graded• Presence or absence DSA (luminex bead) – not routine• C3d staining on strong C4d cases• Pattern of inflammation reassessed in
• Strong C4d bx V highest C4d neg/weak• Busy, no, focal or diffuse infiltrate, Cells in / around capillary
![Page 3: C4d – The Birmingham UK Experience Desley Neil, Majid Mukadam, David Briggs* UHBNHSFT, NHSBT* Birmingham](https://reader036.vdocuments.mx/reader036/viewer/2022070412/56649d2b5503460f94a005ac/html5/thumbnails/3.jpg)
Biopsy protocol• Protocol
– Weekly x 6– Fortnightly x 2– Monthly x 2– 6 weekly x 2 1year– 6 monthly x2 2 years– Yearly x1 3 years
• Indication– Symptomatic or change in echo
• Change of medication– 2-3 biopsy during transition and once established
![Page 4: C4d – The Birmingham UK Experience Desley Neil, Majid Mukadam, David Briggs* UHBNHSFT, NHSBT* Birmingham](https://reader036.vdocuments.mx/reader036/viewer/2022070412/56649d2b5503460f94a005ac/html5/thumbnails/4.jpg)
C4d (& C3d) grading system
• 0 Negative• 1 Weak patchy staining• 2 Moderate staining• 3 Diffuse strong staining
(Looks like CD31 at low power)
• Immunoperoxidase Polyclonal Ab Biomedica
![Page 5: C4d – The Birmingham UK Experience Desley Neil, Majid Mukadam, David Briggs* UHBNHSFT, NHSBT* Birmingham](https://reader036.vdocuments.mx/reader036/viewer/2022070412/56649d2b5503460f94a005ac/html5/thumbnails/5.jpg)
C4d
![Page 6: C4d – The Birmingham UK Experience Desley Neil, Majid Mukadam, David Briggs* UHBNHSFT, NHSBT* Birmingham](https://reader036.vdocuments.mx/reader036/viewer/2022070412/56649d2b5503460f94a005ac/html5/thumbnails/6.jpg)
C3d
![Page 7: C4d – The Birmingham UK Experience Desley Neil, Majid Mukadam, David Briggs* UHBNHSFT, NHSBT* Birmingham](https://reader036.vdocuments.mx/reader036/viewer/2022070412/56649d2b5503460f94a005ac/html5/thumbnails/7.jpg)
Demographics
49 (14-65)49 (14-63) 44 (19-65) Age
132 31 163
![Page 8: C4d – The Birmingham UK Experience Desley Neil, Majid Mukadam, David Briggs* UHBNHSFT, NHSBT* Birmingham](https://reader036.vdocuments.mx/reader036/viewer/2022070412/56649d2b5503460f94a005ac/html5/thumbnails/8.jpg)
Biopsies
• Timing of biopsies– 171 days (0-5806 days) post-tx
• Number of biopsies / patient– 4 (1-40) biopsies
![Page 9: C4d – The Birmingham UK Experience Desley Neil, Majid Mukadam, David Briggs* UHBNHSFT, NHSBT* Birmingham](https://reader036.vdocuments.mx/reader036/viewer/2022070412/56649d2b5503460f94a005ac/html5/thumbnails/9.jpg)
C4d staining
72%
15%
60%
![Page 10: C4d – The Birmingham UK Experience Desley Neil, Majid Mukadam, David Briggs* UHBNHSFT, NHSBT* Birmingham](https://reader036.vdocuments.mx/reader036/viewer/2022070412/56649d2b5503460f94a005ac/html5/thumbnails/10.jpg)
Highest C4d grade / patient
12.3%
35.6%
22.1%29.5%
![Page 11: C4d – The Birmingham UK Experience Desley Neil, Majid Mukadam, David Briggs* UHBNHSFT, NHSBT* Birmingham](https://reader036.vdocuments.mx/reader036/viewer/2022070412/56649d2b5503460f94a005ac/html5/thumbnails/11.jpg)
Death related to highest C4d6.3% 11.1% 20.7% 35%
Kruskal Wallis p<0.02
![Page 12: C4d – The Birmingham UK Experience Desley Neil, Majid Mukadam, David Briggs* UHBNHSFT, NHSBT* Birmingham](https://reader036.vdocuments.mx/reader036/viewer/2022070412/56649d2b5503460f94a005ac/html5/thumbnails/12.jpg)
20.0015.0010.005.000.00
followup
1.0
0.8
0.6
0.4
0.2
0.0
Cu
m S
urv
ival
3-censored
2-censored
1-censored
0-censored
3
2
1
0highestC4d
Survival Functions
![Page 13: C4d – The Birmingham UK Experience Desley Neil, Majid Mukadam, David Briggs* UHBNHSFT, NHSBT* Birmingham](https://reader036.vdocuments.mx/reader036/viewer/2022070412/56649d2b5503460f94a005ac/html5/thumbnails/13.jpg)
Follow up time v highest C4d grade
Follow up 0 1 2 3 missing
N= 48 36 58 20 1
Median(range) 8 yrs
(0.4-16.8)4.4 yrs(0.5-15.5)
3.6yrs(0.3-14.8)
6 yrs(0.6-15.6)
12.4yr
Kruskal Wallis p=0
![Page 14: C4d – The Birmingham UK Experience Desley Neil, Majid Mukadam, David Briggs* UHBNHSFT, NHSBT* Birmingham](https://reader036.vdocuments.mx/reader036/viewer/2022070412/56649d2b5503460f94a005ac/html5/thumbnails/14.jpg)
Strong C4d
• 20 patients• 7 had DSA found• 6/7 (85.7%) with DSA died• 1 with lot of consecutive strong C4d
– serum not sent till after Plasma exchange = negative
– Retransplanted
• Others only HLA Ab tested inconsistently
![Page 15: C4d – The Birmingham UK Experience Desley Neil, Majid Mukadam, David Briggs* UHBNHSFT, NHSBT* Birmingham](https://reader036.vdocuments.mx/reader036/viewer/2022070412/56649d2b5503460f94a005ac/html5/thumbnails/15.jpg)
DSA
• 19 (11.7%) patients• Found 7.1 (0-12.9) years post-tx• 13 (68.6%) class II and 6 (31.4%) class I and II
![Page 16: C4d – The Birmingham UK Experience Desley Neil, Majid Mukadam, David Briggs* UHBNHSFT, NHSBT* Birmingham](https://reader036.vdocuments.mx/reader036/viewer/2022070412/56649d2b5503460f94a005ac/html5/thumbnails/16.jpg)
Demographics of DSA +/-
Age: DSA + 46 (14-59) DSA – 49 (17-65)
NS
![Page 17: C4d – The Birmingham UK Experience Desley Neil, Majid Mukadam, David Briggs* UHBNHSFT, NHSBT* Birmingham](https://reader036.vdocuments.mx/reader036/viewer/2022070412/56649d2b5503460f94a005ac/html5/thumbnails/17.jpg)
Symptoms
• 5 (26.3%) asymptomatic• 14 (73.3%) symptomatic
– 3 IHD/graft vasculopathy– 11 syncope, heart failure
• 10 evidence of graft vasculopathy• 8 no evidence of graft vasculopathy• 1 don’t know
![Page 18: C4d – The Birmingham UK Experience Desley Neil, Majid Mukadam, David Briggs* UHBNHSFT, NHSBT* Birmingham](https://reader036.vdocuments.mx/reader036/viewer/2022070412/56649d2b5503460f94a005ac/html5/thumbnails/18.jpg)
Death related to DSA47.4%18.8%10.5%
Death v DSA Wilcoxin p=0.000
![Page 19: C4d – The Birmingham UK Experience Desley Neil, Majid Mukadam, David Briggs* UHBNHSFT, NHSBT* Birmingham](https://reader036.vdocuments.mx/reader036/viewer/2022070412/56649d2b5503460f94a005ac/html5/thumbnails/19.jpg)
Follow up time v DSA
Not tested Neg PosN= 19 125 19
Median(range) 6.1 yrs
(0.4-15.7)5.2 yrs(0.3-15.8)
8.6yrs(0.9-13.5)
Kruskal Wallis NS
Death8.8 (3-12.9) yrs post tx215 (7-1188) days post DSA found
![Page 20: C4d – The Birmingham UK Experience Desley Neil, Majid Mukadam, David Briggs* UHBNHSFT, NHSBT* Birmingham](https://reader036.vdocuments.mx/reader036/viewer/2022070412/56649d2b5503460f94a005ac/html5/thumbnails/20.jpg)
DSA v highest C4d grade
Kruskal Wallis p=0
35%17.2%2.8%2.1%
![Page 21: C4d – The Birmingham UK Experience Desley Neil, Majid Mukadam, David Briggs* UHBNHSFT, NHSBT* Birmingham](https://reader036.vdocuments.mx/reader036/viewer/2022070412/56649d2b5503460f94a005ac/html5/thumbnails/21.jpg)
DSA v Strong C4d +C3d grade
![Page 22: C4d – The Birmingham UK Experience Desley Neil, Majid Mukadam, David Briggs* UHBNHSFT, NHSBT* Birmingham](https://reader036.vdocuments.mx/reader036/viewer/2022070412/56649d2b5503460f94a005ac/html5/thumbnails/22.jpg)
DSA /Patient with strong C4d +/- mod/strong C3d
60%
P<0.05
![Page 23: C4d – The Birmingham UK Experience Desley Neil, Majid Mukadam, David Briggs* UHBNHSFT, NHSBT* Birmingham](https://reader036.vdocuments.mx/reader036/viewer/2022070412/56649d2b5503460f94a005ac/html5/thumbnails/23.jpg)
DSA in relation to C4d persistence
• Persistent strong 4/6 (66.7%)• Intermittent mod/strong 4/17 (23.5%)• Single strong (others neg/weak) 4/18 (22.2%)• Single bx = strong (no others bx) 3/7 (42.9%)• Nothing much 3/111 (2.7%)
Kruskal-Wallis p<0.02
![Page 24: C4d – The Birmingham UK Experience Desley Neil, Majid Mukadam, David Briggs* UHBNHSFT, NHSBT* Birmingham](https://reader036.vdocuments.mx/reader036/viewer/2022070412/56649d2b5503460f94a005ac/html5/thumbnails/24.jpg)
C3d staining in relation to persistence of C4d
![Page 25: C4d – The Birmingham UK Experience Desley Neil, Majid Mukadam, David Briggs* UHBNHSFT, NHSBT* Birmingham](https://reader036.vdocuments.mx/reader036/viewer/2022070412/56649d2b5503460f94a005ac/html5/thumbnails/25.jpg)
N=357 neg/weakN=42 strong
![Page 26: C4d – The Birmingham UK Experience Desley Neil, Majid Mukadam, David Briggs* UHBNHSFT, NHSBT* Birmingham](https://reader036.vdocuments.mx/reader036/viewer/2022070412/56649d2b5503460f94a005ac/html5/thumbnails/26.jpg)
BUSY “B” PATTERN
![Page 27: C4d – The Birmingham UK Experience Desley Neil, Majid Mukadam, David Briggs* UHBNHSFT, NHSBT* Birmingham](https://reader036.vdocuments.mx/reader036/viewer/2022070412/56649d2b5503460f94a005ac/html5/thumbnails/27.jpg)
Summary• C4d staining relatively uncommon• Both DSA and highest grade of C4d correlates with
death• Correlation between C4d and DSA –? improved by
C3d• Neither C4d or DSA in isolation is sensitive at a
single time point – C4d - comes and goes, precede inflam and symptoms– Repeat DSAs (- to + in 4/7)
![Page 28: C4d – The Birmingham UK Experience Desley Neil, Majid Mukadam, David Briggs* UHBNHSFT, NHSBT* Birmingham](https://reader036.vdocuments.mx/reader036/viewer/2022070412/56649d2b5503460f94a005ac/html5/thumbnails/28.jpg)
• Using ISHLT criteria will miss 2/3 C4d positive cases
• same also if C3d mod/strong• Busy “B” with cells in or around vessels• C4d/C3d needs to be routine
C4d grade